Trial Profile

The effect of Rifampicin on the safety, tolerability, pharmacokinetics and absolute bioavailability of oral and intravenous apixaban in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Apixaban (Primary) ; Rifampicin
Indications Acute coronary syndromes; Stroke; Thromboembolism; Venous thromboembolism
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb; Pfizer

Most Recent Events

21 Jan 2016 New trial record
09 Jan 2016 Results published in the American Journal of Cardiovascular Drugs

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com